ZY Health Loss Hits RMB 924M as Revenue Plummets 53.5%

Edgen Stock

·Mar 27 2026, 02:36

Share to

Share to

Copy link

Key Takeaways

ZY Health (09955.HK) reported dire full-year financial results, revealing a severe contraction in its business. The company's revenue more than halved while its net loss widened significantly, signaling deep operational and financial distress that will likely alarm investors.

Revenue Collapse: Full-year revenue for the period ending in December fell by 53.5% year-over-year to RMB 1.623 billion.
Widening Losses: The company's net loss expanded to RMB 924 million, a sharp increase from the RMB 516 million loss recorded in the prior year.
Shareholder Pain: ZY Health announced a loss per share of RMB 1.52 and confirmed it would not be declaring a dividend.

Revenue Collapses 53.5% to RMB 1.623 Billion

ZY Health (09955.HK) disclosed a severe downturn in its full-year performance for the period ending last December. The company's revenue was slashed by more than half, falling 53.5% year-over-year to RMB 1.623 billion. This precipitous drop in top-line performance points to significant headwinds and a potential crisis in its core business operations, raising immediate questions about its market position and product demand.

Net Loss Swells 79% to RMB 924 Million

The sharp decline in revenue directly impacted ZY Health's bottom line, causing its net loss to widen substantially. The company reported a full-year loss of RMB 924 million, marking a 79% deterioration from the RMB 516 million loss posted in the previous year. This inability to manage costs against falling sales indicates escalating financial pressure and a failure to stabilize the business model.

LPS Hits RMB 1.52 Amid No Dividend Payout

For shareholders, the financial results translate into a loss per share (LPS) of RMB 1.52. Underscoring the company's precarious financial state, the board announced that no dividend would be declared. The combination of deepening losses and the cancellation of shareholder returns is likely to erode investor confidence and could trigger a significant sell-off in the company's stock, prompting concerns about its long-term viability.